2 Information about ravulizumab

Marketing authorisation indication

2.1 Ravulizumab (Ultomiris, Alexion Pharmaceuticals) is indicated for 'the treatment of patients with a body weight of 10 kg or above with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naive or have received eculizumab for at least 3 months and have evidence of response to eculizumab'.

Dosage in the marketing authorisation

2.2 The dosage schedule is available in the summary of product characteristics.


2.3 The list price is £4,533 for 300 mg per 3 ml concentrate for solution for infusion vial; £16,621 for 1,100 mg per 11 ml concentrate for solution for infusion vial (excluding VAT; company submission).

2.4 The company has a commercial arrangement (simple discount patient access scheme). This makes ravulizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.

  • National Institute for Health and Care Excellence (NICE)